Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates
HER3-DXd and T-DXd are antibody-drug conjugates (ADCs) that induce immunogenic cell death and bystander killing, enhancing antitumor immunity beyond target-specific cytotoxicity. These findings highlight novel mechanisms that can overcome antigen heterogeneity and suggest opportunities for improving...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2533488 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850105268738719744 |
|---|---|
| author | Oliver Kepp Guido Kroemer |
| author_facet | Oliver Kepp Guido Kroemer |
| author_sort | Oliver Kepp |
| collection | DOAJ |
| description | HER3-DXd and T-DXd are antibody-drug conjugates (ADCs) that induce immunogenic cell death and bystander killing, enhancing antitumor immunity beyond target-specific cytotoxicity. These findings highlight novel mechanisms that can overcome antigen heterogeneity and suggest opportunities for improving ADC design and therapeutic synergy through informed combination with immunotherapies. |
| format | Article |
| id | doaj-art-ee6693d2d6b945aaae663b597fca26a6 |
| institution | OA Journals |
| issn | 2162-402X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-ee6693d2d6b945aaae663b597fca26a62025-08-20T02:39:08ZengTaylor & Francis GroupOncoImmunology2162-402X2025-12-0114110.1080/2162402X.2025.2533488Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugatesOliver Kepp0Guido Kroemer1Université Paris Cité, Sorbonne Université, Inserm, Centre de Recherche des Cordeliers, Equipe labellisée parla Ligue contre le cancer, Institut Universitaire de France, Paris, FranceUniversité Paris Cité, Sorbonne Université, Inserm, Centre de Recherche des Cordeliers, Equipe labellisée parla Ligue contre le cancer, Institut Universitaire de France, Paris, FranceHER3-DXd and T-DXd are antibody-drug conjugates (ADCs) that induce immunogenic cell death and bystander killing, enhancing antitumor immunity beyond target-specific cytotoxicity. These findings highlight novel mechanisms that can overcome antigen heterogeneity and suggest opportunities for improving ADC design and therapeutic synergy through informed combination with immunotherapies.https://www.tandfonline.com/doi/10.1080/2162402X.2025.2533488CancerCD47cell stressimmunotherapy |
| spellingShingle | Oliver Kepp Guido Kroemer Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates OncoImmunology Cancer CD47 cell stress immunotherapy |
| title | Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates |
| title_full | Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates |
| title_fullStr | Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates |
| title_full_unstemmed | Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates |
| title_short | Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates |
| title_sort | immunogenic cell death and bystander killing expanding the therapeutic potential of modern antibody drug conjugates |
| topic | Cancer CD47 cell stress immunotherapy |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2533488 |
| work_keys_str_mv | AT oliverkepp immunogeniccelldeathandbystanderkillingexpandingthetherapeuticpotentialofmodernantibodydrugconjugates AT guidokroemer immunogeniccelldeathandbystanderkillingexpandingthetherapeuticpotentialofmodernantibodydrugconjugates |